Sorry, you need to enable JavaScript to visit this website.

MILRINONE LACTATE (milrinone lactate injection) Dosage and Administration

DOSAGE AND ADMINISTRATION

Milrinone lactate injection should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:

LOADING DOSE  

50 mcg/kg: Administer slowly over 10 minutes

The table below shows the loading dose in milliliters (mL) of Milrinone lactate injection (1mg/mL) by patient body weight (kg).

Loading Dose (mL) Using 1 mg/mL Concentration

Patient Body Weight (kg)

kg

30

40

50

60

70

80

90

100

110

120

mL

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

The loading dose may be given undiluted, but diluting to a rounded total volume of 10 or 20 mL (see Maintenance Dose for diluents) may simplify the visualization of the injection rate.

MAINTENANCE DOSE

 



Infusion Rate

Total Daily
Dose

(24 hours)

 

Minimum

0.375 mcg/kg/min

0.59 mg/kg

Administer as a continuous intravenous infusion.

Standard

0.5 mcg/kg/min

0.77 mg/kg

Maximum

0.75 mcg/kg/min

1.13 mg/kg

Milrinone lactate injection drawn from vials should be diluted prior to maintenance dose administration. The diluents that may be used are 0.45% Sodium Chloride Injection, USP; 0.9% Sodium Chloride Injection, USP; or 5% Dextrose Injection, USP. The table below shows the volume of diluent in milliliters (mL) that must be used to achieve 200 mcg/mL concentration for infusion, and the resultant total volumes.

Desired Infusion

Concentration

mcg/mL

Milrinone

1 mg/mL

(mL)

Diluent

(mL)

Total Volume

(mL)

200

10

40

50

200

20

80

100

The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure.

Note: See " Dosage Adjustment in Renally Impaired Patients ." Dosage may be titrated to the maximum hemodynamic effect and should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.

The maintenance dose in mL/hr by patient body weight (kg) may be determined by reference to the following table.

Milrinone Infusion Rate (mL) Using 200 mcg/mL Concentration

Maintenance Dose

(mcg/kg/min)

Patient Body Weight (kg)

30

40

50

60

70

80

90

100

110

120

0.375

3.4

4.5

5.6

6.8

7.9

9

10.1

11.3

12.4

13.5

0.4

3.6

4.8

6

7.2

8.4

9.6

10.8

12

13.2

14.4

0.5

4.5

6

7.5

9

10.5

12

13.5

15

16.5

18

0.6

5.4

7.2

9

10.8

12.6

14.4

16.2

18

19.8

21.6

0.7

6.3

8.4

10.5

12.6

14.7

16.8

18.9

21

23.1

25.2

0.75

6.8

9

11.3

13.5

15.8

18

20.3

22.5

24.8

27

When administering milrinone lactate by continuous infusion, it is advisable to use a calibrated electronic infusion device.

Dosage Adjustment in Renally Impaired Patients

Data obtained from patients with severe renal impairment (creatinine clearance = 0 to 30 mL/min) but without congestive heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. Reductions in infusion rate may be necessary in patients with renal impairment. For patients with clinical evidence of renal impairment, the recommended infusion rate can be obtained from the following table:

Creatinine Clearance Infusion Rate

Creatinine Clearance

(mL/min/1.73 m 2 )

Infusion Rate

(mcg/kg/min)

5

0.2

10

0.23

20

0.28

30

0.33

40

0.38

50

0.43

Intravenous drug products should be inspected visually and should not be used if particulate matter or discoloration is present.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for MILRINONE LACTATE
×

Sollten Sie Probleme mit der Anmeldung über Ihr DocCheck Konto haben, deaktivieren Sie „Cross-Sitetracking verhindern“ unter Einstellungen / Safari / Datenschutz & Sicherheit.

×

Ihre derzeitige Browsereinstellung erlaubt keine Anmeldung über Ihr DocCheck Konto. Bitte wählen Sie den „Desktop-Version“ Modus unter dem Dreipunkt-Menu Ihres Browsers.

×

Safari-Nutzer: Sollten Sie Probleme mit der Anmeldung über Ihr DocCheck Konto haben, deaktivieren Sie „Cross-Sitetracking verhindern“ unter Einstellungen / Safari / Datenschutz & Sicherheit.